Astrazeneca Says Phase 3 Lung Cancer Trial Failed to Meet Primary Endpoint of Overall Survival

MT Newswires Live12-22 18:29

AstraZeneca (AZN) said Monday its Latify phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet the primary endpoint of overall survival, compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer.

The trial evaluated patients without actionable genomic alterations whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.

The combination drug was generally well tolerated, with data set to be presented at a forthcoming medical meeting, the company said.

The trial, conducted across over 20 countries with 594 patients, had a primary endpoint of overall survival, and secondary endpoints included progression-free survival, objective response rate, and duration of response, among others.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593486098?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 18:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593486098","market":"sg","top_or_hot":-1,"title":"Astrazeneca Says Phase 3 Lung Cancer Trial Failed to Meet Primary Endpoint of Overall Survival","media":"MT Newswires Live","content":"<html><body><p> AstraZeneca (AZN) said Monday its Latify phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet the primary endpoint of overall survival, compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer.</p><p>The trial evaluated patients without actionable genomic alterations whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.</p><p>The combination drug was generally well tolerated, with data set to be presented at a forthcoming medical meeting, the company said.</p><p>The trial, conducted across over 20 countries with 594 patients, had a primary endpoint of overall survival, and secondary endpoints included progression-free survival, objective response rate, and duration of response, among others.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astrazeneca Says Phase 3 Lung Cancer Trial Failed to Meet Primary Endpoint of Overall Survival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstrazeneca Says Phase 3 Lung Cancer Trial Failed to Meet Primary Endpoint of Overall Survival\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-22 18:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AstraZeneca (AZN) said Monday its Latify phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet the primary endpoint of overall survival, compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer.</p><p>The trial evaluated patients without actionable genomic alterations whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.</p><p>The combination drug was generally well tolerated, with data set to be presented at a forthcoming medical meeting, the company said.</p><p>The trial, conducted across over 20 countries with 594 patients, had a primary endpoint of overall survival, and secondary endpoints included progression-free survival, objective response rate, and duration of response, among others.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593486098","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593486098","pubTimestamp":1766399359,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AstraZeneca  said Monday its Latify phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet the primary endpoint of overall survival, compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer.The trial evaluated patients without actionable genomic alterations whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.The combination drug was generally well tolerated, with data set to be presented at a forthcoming medical meeting, the company said.The trial, conducted across over 20 countries with 594 patients, had a primary endpoint of overall survival, and secondary endpoints included progression-free survival, objective response rate, and duration of response, among others.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4568":"美国抗疫概念","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","AZN":"阿斯利康"},"translate_title":"阿斯利康称肺癌3期试验未能达到总生存期主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"AstraZeneca (AZN) said Monday its Latify phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet the primary endpoint of overall survival, compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer.The trial evaluated patients without actionable genomic alterations whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.The combination drug was generally well tolerated, with data set to be presented at a forthcoming medical meeting, the company said.The trial, conducted across over 20 countries with 594 patients, had a primary endpoint of overall survival, and secondary endpoints included progression-free survival, objective response rate, and duration of response, among others.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593486098","isCrawlerRequest":true}